Gatifloxacin

Zymar · TEQUIN · CG5501 · S)-AHPC · Gatiquin · PD135432 · PD 135432 · PD-135432)

Identifikatoren & physikalische Daten

CAS No.	112811-59-3
Summenformel	C19H22FN3O4
Durchschnittliche Molmasse	375,4 g/mol
Monoisotopische Masse	375,1594344 g/mol
SMILES	COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
InChIKey	XUBOMFCQGDBHNK-UHFFFAOYSA-N
PubChem CID	5379
ChEMBL	CHEMBL31
ChEBI	CHEBI:5280
EC No.	664-293-2
DTXSID	DTXSID5045704

Chemische & physikalische Eigenschaften

XLogP	-0,7
Polarare Oberfläche (TPSA)	82,1
H-Brücken-Donoren	2
H-Brücken-Akzeptoren	8
Frei drehbare Bindungen	4
Schwere Atome	27
Formalladung	0
Komplexität	653
Arzneimittel	Pharmaceuticals -> AntibioticsPharmaceuticals -> Anti infectives for systemic use -> Antibacterials for systemic use
LogP (Verteilungskoeffizient)	2.6
Löslichkeit	6.31e-01 g/LChloroform (Slightly, Heated), Methanol (Slightly, Heated)
Human Drugs	Breast FeedingLactationMilk, HumanAnti-Infective AgentsAntibacterial AgentsQuinolonesFluoroquinolonesFDA approved drugs -> Active ingredient
Schmelzpunkt	182-185 °C182 - 185 °C162°C
Physical Description	Solid
Dissociation Constants	8.7469.4
Collision Cross Section	189.5 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]189.03 Å² [M+H]+ [CCS Type: TW
Siedepunkt	607.8±55.0 °C(Predicted)
Dichte	1.386±0.06 g/cm3(Predicted)
Lagerbedingungen	Sealed in dry,2-8°C
pKa (Säurekonstante)	6.43±0.50(Predicted)
Aggregatzustand	White to yellow crystalline powder.
Farbe	White to Off-White
Hauptanwendungen	pharmaceutical (small molecule)
InChI	InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
InChIKey	XUBOMFCQGDBHNK-UHFFFAOYSA-N
SMILES	N1(C2CC2)C2=C(C=C(F)C(N3CCNC(C)C3)=C2OC)C(=O)C(C(O)=O)=C1
CAS Datenbank	112811-59-3(CAS DataBase Reference)

Sicherheit & Vorschriften

GHS-Einstufung	WarningH302 (97.5%): Harmful if swallowed [Warning Acute toxicity, oral]P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard Classes and Categories	Acute Tox. 4 (97.5%)
Treatment	In the event of acute oral overdose, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be carefully observed (including ECG monitoring) and given symptomatic and supportive treatment. Adequate hydration should be maintained. (L1712)
Gesundheitliche Auswirkungen	Antibiotic resistance
Expositionspfade	Ophthalmic. Well absorbed from the gastrointestinal tract after oral administration with absolute bioavailability of gatifloxacin is 96%
Toxizitätsübersicht	The bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
Signs and Symptoms	The most common side effects from antibiotics are diarrhea, nausea, vomiting. Fungal infections of the mouth, digestive tract and vagina can also occur with antibiotics
Carcinogen Classification	No indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation	◉ Summary of Use during Lactation
Wassergefährdungsklasse (WGK)	WGK 1
Zollcode	29335990
R-Sätze (R)	20/21/22
Gefahrensymbole	Xn
Sicherheitshinweise (S)

Anwendungen & Verwendung

Beschreibung

Gatifloxacin belongs to a class of drugs known as quinolone antibiotics and is used to treat acute sinus, lung, or urinary tract infections and sexually transmitted bacterial infection.This drug may be taken orally, in tablet form, or by injection.Common side effects associated with gatifloxacin include nausea, vaginitis(irritation or inflammation of the vagina)，diarrhea, headache, dizziness, and irregular heart beats. In general, gatifloxacin is used in people who are unresponsive to other AOM therapies.In one study, gatifloxacin was compared with amoxicillin/clavulanate in the treatment of recurrent otitis media (OM) and AOM in treatment failures in children.Three hundred fifty-four infants and children with recurrent OM or AOM failure received gatifloxacin or amoxicillin/clavulanate.Results showed that both drugs were well tolerated; the most common side effect was diarrhea.Researchers concluded that treatment with gatifloxacin once daily was as effective as amoxicillin/clavulanate twice daily.In other medical literature, gatifloxacin has been noted as a third-line treatment option in AOM.